Daily low-dose carboplatin or weekly carboplatin plus nab-paclitaxel for concurrent chemoradiotherapy in older patients with locally advanced non-small cell lung cancer (JCOG1914): A randomized phase 3 trial

Study limitation reported by the research below: “Trial was terminated early for futility after interim analysis; final OS data are immature (median not reached in control arm), so survival estimates should be interpreted cautiously.”